Outsourcing Innovation eBook February 2024
Read the article: A Closer Look at Affinity Ligands
Feature|Articles|February 15, 2024
- Bio/Pharma Outsourcing Innovation, February 2024 eBook
- Volume 2024 eBook
- Issue 2
- Pages: 16-21
A Closer Look at Affinity Ligands
Author(s)Daria G. Husni
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
Advertisement
Affinity ligands play an exciting role in the ever-growing sphere of downstream processing. In speaking with Pharmaceutical Technology®, Phillip Elliott, PhD, associate director of Process Development, BioCina; Jan Bekker, PhD, director, Business Development, Commercial and Technical Operations, BioCina; and Parviz Shamlou, PhD, senior vice-president of Science & Technology, Abzena illuminate the newest innovations with affinity ligands and provide a deeper understanding of the role affinity ligands play in the future of downstream processing.
Read this article in Pharmaceutical Technology’s Bio/Pharma Outsourcing Innovation eBook.
About the author
Daria Husni is assistant editor to Pharmaceutical Technology® and Pharmaceutical Technology Europe®.
Article details
Pharmaceutical Technology/Pharmaceutical Technology Europe Outsourcing Innovation eBook
Issue 2
February 2024
Pages: 16-21
Citation
When referring to this article, please cite it as Husni, D. A Closer Look at Affinity Ligands. Pharmaceutical Technology, Bio/Pharma Outsourcing Innovation eBook. February 2024.
Articles in this issue
over 2 years ago
Pharmaceutical Outsourcing Present and Futureover 2 years ago
Managing the Complexity of Modern Sterile Product Developmentsover 2 years ago
Navigating the Preclinical CRO Outsourcing Processover 2 years ago
Ensuring Quality in Contracted Supportover 2 years ago
How to Evaluate a CDMO’s Commitment to QualityAdvertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5